Ad
Wednesday, 14 June 2017
BioTime's Renevia succeeds in pivotal European facial wasting trial
(Reuters) - BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment